• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prediction of ischaemic stroke in non-valvular atrial fibrillation if advanced echocardiography plays the game
Abstract
Source: European Heart Journal - February 9, 2018 Category: Cardiology Source Type: research

Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation
Abstract
Source: European Heart Journal - January 6, 2018 Category: Cardiology Source Type: research

Corrigendum to: Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials
Eur Heart J (2017) 38 (10):742 –750.
Source: European Heart Journal - June 1, 2017 Category: Cardiology Source Type: research

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
ConclusionCompared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.
Source: European Heart Journal - April 13, 2018 Category: Cardiology Source Type: research

Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation
This editorial refers to ‘Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study’††, by L. Staerket al., on page 1698.
Source: European Heart Journal - December 13, 2017 Category: Cardiology Source Type: research

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
Source: European Heart Journal - September 21, 2019 Category: Cardiology Source Type: research

Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial
Results of the ELDERCARE-AF trial have been presented at the ESC Congress 2020 and simultaneously published in theNew England Journal of Medicine (https://doi.org/10.1056/NEJMoa2012883).
Source: European Heart Journal - November 4, 2020 Category: Cardiology Source Type: research

Prevalence, incidence, and outcomes across cardiovascular diseases in homeless individuals using national linked electronic health records
Conclusion  CVD in homeless individuals has high prevalence, incidence, and 1-year mortality risk post-diagnosis with earlier onset, and high burden of risk factors. Inclusion health and social care strategies should reflect this high preventable and treatable burden, which is increasingly important in the current COVID-19 context.
Source: European Heart Journal - September 10, 2020 Category: Cardiology Source Type: research

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
Conclusions  In patients with AF who underwent PCI, the edoxaban-based regimen, as compared with VKA-based regimen, provides consistent safety and similar efficacy for ischaemic events in patients with AF regardless of their clinical presentation.
Source: European Heart Journal - August 29, 2020 Category: Cardiology Source Type: research

The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH
Key pointsSTRENGTH,1 an industry-sponsored, double-blind, randomized, controlled trial investigated the effects of a carboxylic acid (CA) formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (omega-3 CA) vs. corn oil in 13 078 participants with high cardiovascular (CV) risk, hypertriglyceridaemia, and low levels of high-density lipoprotein cholesterol.Eligible patients were randomized to receive 4 g/day of omega-3 CA or corn oil in addition to standard preventive therapies, including statins (high-intensity in 50%), renin-angiotensin-aldosterone system (RAAS) blockers (in 81%), and antiplatelet agents ...
Source: European Heart Journal - February 1, 2021 Category: Cardiology Source Type: research

Valvular atrial fibrillation and a CHA2DS2-VASc score of 1 —a statement of the ESC working group on cardiovascular pharmacotherapy and ESC council on stroke
This commentary refers to ‘2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)’ by G. Hindrickset al., 2021;42:373--498.
Source: European Heart Journal - January 26, 2021 Category: Cardiology Source Type: research

Late device-related thrombus after left atrial appendage closure: never let your guard down
Left atrial appendage closure (LAAC) is an established strategy for stroke prevention in patients with non-valvular atrial fibrillation and contraindications for oral anticoagulation. Device-related thrombus (DRT) is a feared short-term complication with an incidence of 4 –17%. Data regarding the likelihood of late DRT are scarce.
Source: European Heart Journal - November 12, 2020 Category: Cardiology Source Type: research

Decoding stroke risk scores in atrial fibrillation: still more work to do
Source: European Heart Journal - April 6, 2021 Category: Cardiology Source Type: research

All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study
ConclusionsAmong patients with established cardiovascular disease, the in-hospital mortality rate was lower and out-of-hospital mortality rate higher during lockdown compared with the same period in the preceding year, irrespective of age and sex.
Source: European Heart Journal - February 24, 2021 Category: Cardiology Source Type: research

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
ConclusionPatients with childhood-onset HCM are more likely to have sarcomeric disease, carry a higher risk of life-threatening ventricular arrythmias, and have greater need for advanced HF therapies. These findings provide insight into the natural history of disease and can help inform clinical risk stratification.
Source: European Heart Journal - March 26, 2021 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5  6  7  8